Multimodal treatment of an advanced intrahepatic cholangiocarcinoma and its recurrence – a case report

Multimodal treatment of an advanced intrahepatic cholangiocarcinoma and its recurrence – a case report

Lisa-Katharina Heuft¹, Arndt Weinmann², Roman Kloeckner³, Tiemo S. Gerber⁴, Fabian Bartsch^1,‡,* and Hauke Lang^1,‡,*

¹ Department of General, Visceral and Transplant Surgery; ² Department of Internal Medicine; ³ Department of Diagnostic and Interventional Radiology; ⁴ Institute of Pathology; University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, ‡ Shared senior authorship and correspondence

Introduction: Intrahepatic cholangiocarcinoma (ICC) is rare and often diagnosed in an advanced stage. Neoadjuvant therapy is not established and data on its value are in palliative intention. In the case of a recurrence patients often are offered systemic chemotherapy as the only treatment option. We report on a patient with advanced intrahepatic cholangiocarcinoma who underwent multimodal treatment leading to a long-term survival.

Case report: A 61-year-old woman presented with an advanced intrahepatic cholangiocarcinoma of the right liver lobe without evidence of metastatic spread. She had already completed two cycles of chemotherapy of Cisplatin and Gemcitabine resulting in stable disease. An extended hemihepatectomy of the right lobe including segments I, IVa and partially IVb was performed. The TNM status (8th edition) was pT2b (3), pN0 (0/6), M0, V1, G2 and R0. Ten months later recurrence was diagnosed and treated with microwave ablation. Recurrence occurred again and the patient underwent repeated resection 22 months after primary resection. After detection of repeated recurrence once more, repeated resection was performed 46 months after initial resection. The patient is still alive and tumor-free 7 years after primary resection.

Conclusion: Multimodal treatment including preoperative chemotherapy, complete resection and repeated resection of recurrence as well as microwave ablation led to long-term survival in a case of advanced intrahepatic cholangiocarcinoma. Close follow-ups were crucial to offer the best treatment options.

Keywords: Multimodal treatment; advanced intrahepatic cholangiocarcinoma; case report

Free Full-text PDF

How to cite this article:

Lisa-Katharina Heuft, Arndt Weinmann, Roman Kloeckner, Tiemo S. Gerber, Fabian Bartsch, Hauke Lang. Multimodal treatment of an advanced intrahepatic cholangiocarcinoma and its recurrence – a case report. International Journal of Case Reports, 2021, 6:261. DOI: 10.28933/ijcr-2021-11-1005

References:

1. Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6[2]:101-4.
2. Bartsch F, Tripke V, Baumgart J, Hoppe-Lotichius M, Heinrich S, Lang H. Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study. Int J Surg. 2019 Jul;67:62-69. doi: 10.1016/j.ijsu.2019.05.006. Epub 2019 May 20. PMID: 31121329.
3. Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol. 2020;12[10]:693-708. doi:10.4254/wjh.v12.i10.693
4. Lang H, Sotiropoulos GC, Fruhauf NR, Domland M, Paul A, Kind EM, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma [ICC]: when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005;241[1]:134-43.
5. Bartsch, Fabian et al. “Influence of Lymphangio [L], Vascular [V], and Perineural [Pn] Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma.” Journal of clinical medicine vol. 10,11 2426. 30 May. 2021, doi:10.3390/jcm10112426
6. 6 Lang H. Should all intrahepatic cholangiocarcinomas receive neoadjuvant chemotherapy before resection? Br J Surg. 2021 Jun 22;108[6]:598-599. doi: 10.1093/bjs/znab077. PMID: 33723597.
7. Le Roy B, Gelli M, Pittau G, Allard MA, Pereira B, Serji B, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2017.
8. Buettner S, Koerkamp BG, Ejaz A, Buisman FE, Kim Y, Margonis GA, et al. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis. J Surg Oncol. 2017;115[3]:312-8.
9. Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. ASCO 2017; Abstract 4006. 2017.
10. Bartsch F, Baumgart J, Hoppe-Lotichius M, Schmidtmann I, Heinrich S, Lang H. Visceral infiltration of intrahepatic cholangiocarcinoma is most prognostic after curative resection – Retrospective cohort study of 102 consecutive liver resections from a single center. Int J Surg. 2018;55:193-200.
11. Lang H. Surgical Approach to Recurrent Cholangiocarcinoma. Visc Med. 2021 Feb;37[1]:26-31. doi: 10.1159/000513711. Epub 2020 Dec 21. PMID: 33718481; PMCID: PMC7923921.
12. Bartsch F, Paschold M, Baumgart J, Hoppe-Lotichius M, Heinrich S, Lang H. Surgical resection for recurrent intrahepatic cholangiocarcinoma. World J Surg. 2019.
13. Zhang SJ, Hu P, Wang N, Shen Q, Sun AX, Kuang M, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2013;20[11]:3596-602.
14. Nakagawa A, Igami T, Sugawara G, Ebata T, Yokoyama Y, Takahashi Y, et al. Hepatobiliary resection with concomitant resection of the inferior vena cava for advanced intrahepatic cholangiocarcinoma: report of a case. Surg Today. 2013;43[11]:1321-5.
15. Spolverato G, Kim Y, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, et al. Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Ann Surg Oncol. 2016;23[1]:235-43.
16. Aoki Y, Suzuki T, Kato A, Shimizu H, Ohtsuka M, Yoshitomi H, et al. [A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma]. Gan To Kagaku Ryoho. 2014;41[12]:1509-11.
17. Uji M, Mizuno T, Ebata T, Sugawara G, Igami T, Uehara K, et al. A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin [CAPOX] therapy combined with bevacizumab: a case report. Surgical case reports. 2016;2[1]:63.
18. Reames BN, Bagante F, Ejaz A, Spolverato G, Ruzzenente A, Weiss M, et al. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. HPB [Oxford]. 2017.
19. Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111[2]:213-20.
20. Kamphues C, Seehofer D, Eisele RM, Denecke T, Pratschke J, Neumann UP, et al. Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation. J Hepatobiliary Pancreat Sci. 2010;17[4]:509-15.
21. Tsilimigras, D. I., Sahara, K., Wu, L., Moris, D., Bagante, F., Guglielmi, A., Aldrighetti, L., Weiss, M., Bauer, T. W., Alexandrescu, S., Poultsides, G. A., Maithel, S. K., Marques, H. P., Martel, G., Pulitano, C., Shen, F., Soubrane, O., Koerkamp, B. G., Moro, A., Sasaki, K., … Pawlik, T. M. [2020]. Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. JAMA surgery, 155[9], 823–831. https://doi.org/10.1001/jamasurg.2020.1973